SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
9924 W 74TH ST EDEN PRAIRIE, MN 55344, USA Phone: 6128292700 Fax: 952-500-7001 Web: http://www.surmodics.com/
Industry:MED PRODUCTS Sector: Medical Fiscal Year End:September Last Reported Quarter:03/31/12 Next EPS Date:08/08/12
